title: Treatment of relapsed acute lymphocytic leukemia in adults.
abstract: Thirty-three patients with ALL/AUL in first relapse were treated with an induction of prednisone, vindesine, daunorubicin, Erwinia asparaginase, i.t. MTX (phase I), high-dose cytarabine, and etoposide (phase II). Twenty-one (64%) achieved a complete remission, one a partial remission. Side effects of induction-phase I were predominantly hematological with subsequent infections and gastrointestinal toxicity. In phase II some patients had additional cutaneous, ocular, and hepatic toxicity. The treatment efficiently induced remissions with tolerable toxicity in relapsed ALL. The disease-free survival, however, needs to be improved.
authors.affiliation: Dept. of Hematology/Oncology, Medical School, Hannover, FRG.
authors.forename: M
authors.initials: M
authors.lastname: Freund
authors.forename: M
authors.initials: M
authors.lastname: De Boben
authors.forename: H
authors.initials: H
authors.lastname: Diedrich
authors.forename: A
authors.initials: A
authors.lastname: Ganser
authors.forename: G
authors.initials: G
authors.lastname: Heil
authors.forename: A
authors.initials: A
authors.lastname: Heyll
authors.forename: M
authors.initials: M
authors.lastname: Henke
authors.forename: W
authors.initials: W
authors.lastname: Hiddemann
authors.forename: U
authors.initials: U
authors.lastname: Knauf
authors.forename: P
authors.initials: P
authors.lastname: Koch
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage; D016026:Bone Marrow Transplantation; D001932:Brain Neoplasms / Q000188:drug therapy; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005860:Germany, West / Q000453:epidemiology; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D002955:Leucovorin / Q000008:administration & dosage; D015993:Life Tables; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000601:surgery; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D011241:Prednisone / Q000008:administration & dosage; D013120:Spinal Cord Neoplasms / Q000188:drug therapy; D013713:Teniposide / Q000008:administration & dosage; D013736:Testicular Neoplasms / Q000188:drug therapy; D014751:Vindesine / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D005047:Etoposide; D003907:Dexamethasone; D013713:Teniposide; D001215:Asparaginase; D002955:Leucovorin; D014751:Vindesine; D007069:Ifosfamide; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin